Insider Selling: Disc Medicine (NASDAQ:IRON) COO Sells $21,750.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 300 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $72.50, for a total transaction of $21,750.00. Following the completion of the sale, the chief operating officer directly owned 54,324 shares in the company, valued at approximately $3,938,490. This trade represents a 0.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The stock was sold at an average price of $72.66, for a total transaction of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The stock was sold at an average price of $69.19, for a total transaction of $1,287,764.28.

Disc Medicine Stock Up 1.7%

Disc Medicine stock opened at $76.26 on Friday. The firm has a 50 day simple moving average of $69.23 and a 200 day simple moving average of $70.39. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04. Disc Medicine, Inc. has a 1-year low of $40.00 and a 1-year high of $99.50. The firm has a market capitalization of $2.91 billion, a price-to-earnings ratio of -11.52 and a beta of 0.97.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by ($0.03). On average, analysts predict that Disc Medicine, Inc. will post -6.74 earnings per share for the current year.

Analysts Set New Price Targets

IRON has been the topic of a number of recent research reports. Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. Wedbush reiterated an “outperform” rating and set a $88.00 price target on shares of Disc Medicine in a research report on Wednesday, June 10th. Finally, Morgan Stanley increased their price target on shares of Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Disc Medicine has a consensus rating of “Moderate Buy” and a consensus price target of $104.44.

Institutional Investors Weigh In On Disc Medicine

Several large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its holdings in shares of Disc Medicine by 110.0% in the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock valued at $125,557,000 after acquiring an additional 828,248 shares in the last quarter. BVF Inc. IL purchased a new position in shares of Disc Medicine during the fourth quarter worth about $51,616,000. Jennison Associates LLC bought a new position in shares of Disc Medicine in the fourth quarter worth approximately $42,252,000. Perceptive Advisors LLC bought a new position in shares of Disc Medicine in the fourth quarter worth approximately $35,794,000. Finally, RA Capital Management L.P. raised its stake in Disc Medicine by 25.3% in the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock valued at $156,925,000 after purchasing an additional 399,026 shares in the last quarter. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.